Proton LLC is a startup company, developing an innovative antithrombotic drug GRS for treating cardiovascular diseases. GRS (new small molecule, new mechanism of action) is patented in USA, EU and Russia. GRS is the first-in-class antithrombotic drug – a soluble guanylyl cyclase stimulator. Thanks to its mechanism of action, GRS prevents atherothrombosis simultaneously at 3 levels: reversibly inhibits platelet aggregation, normalizes blood pressure and prevents atherosclerosis (unlike the known antithrombotic drugs).
Currently preclinical trials are completed; phase I clinical trial will be completed in March 2020.
Proton aims to commercialize GRS project in the USA and the EU by opening a subsidiary there (2020), attracting investments and performing Phase II and III clinical trials (2020-2025) with subsequent sale of the project to a Pharma company (2023-2025).
Proton is part of IPHAR company group, which includes: IPHAR R&D center for preclinical and clinical trials; 10 startups with innovative drug projects; licensed drug and food supplement production companies.